iRhythm Holdings shares climbed 5.0% during the most recent trading session, supported by volume that was approximately 30% higher than the 30-day average. This uptick follows four consecutive weeks of positive revisions to consensus earnings estimates, with analysts raising full-year 2025 EPS projections by an average of 8% over that period. Institutional buying accounted for nearly 60% of total volume, according to block trade data, suggesting growing confidence among large investors in the company’s near-term profitability trajectory.

The company reported that full-year 2025 revenue is expected to surpass the high end of its prior $720–740 million guidance, driven by record Zio monitor placements during the fourth quarter. For fiscal 2026, iRhythm projects revenue of $870–880 million, representing year-over-year growth of 17–18% versus a consensus street forecast of $863 million. Management also targets an adjusted EBITDA margin in the range of 11.5–12.5%, underscoring a focus on scaling operational leverage as adoption of its diagnostic platform accelerates in primary care and population health settings.

Despite a roughly 20% share price selloff following confirmation of a Zio MCT launch delay into 2027 and guidance that slightly trailed street expectations, William Blair analyst Brandon Vazquez maintains an Outperform rating. He attributes the pullback to short-term disappointment over the timing shift and sees limited regulatory risk, noting management’s confidence in addressing any FDA feedback within the next 12 months. At about 7 times projected 2026 sales, Vazquez has added the stock to his Conviction List, calling the reset in valuation a compelling entry point for investors focused on long-term growth drivers.